Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH003 with Pembrolizumab and Nab-paclitaxel in Mucosal Melanoma
NCT05420324Phase 2Completed
- Sponsor
- Eucure Biopharma
- Start
- Jun 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ciltistotug in mucosal melanoma (MM), sponsored by Eucure Biopharma. Started Jun 2022; status: completed.
02
Drugs
ciltistotug
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT05420324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05420324.